Market overview
The global at-home syphilis testing market is worth USD 58 mn in 2026 and is forecast to reach USD 495 mn by 2036, growing at a 24.0% CAGR. United States is the largest country market and Rapid antibody tests is the largest by test type segment.
| Scope | Home-use tests for syphilis: rapid finger-prick antibody tests and mail-in dried blood spot kits sold online, through pharmacies and to public health programmes. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 45 mn |
| Value 2026 | USD 58 mn |
| Value 2036 | USD 495 mn |
| CAGR 2026-2036 | 24.0% |
| Volume 2026 | 1.44 million tests |
| Volume 2036 | 15.1 million tests |
| Average price 2026 | USD 40.1 per test |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
At-Home Syphilis Testing market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 58 mn |
| 2027 | USD 71 mn |
| 2028 | USD 89 mn |
| 2029 | USD 110 mn |
| 2030 | USD 136 mn |
| 2031 | USD 169 mn |
| 2032 | USD 209 mn |
| 2033 | USD 260 mn |
| 2034 | USD 322 mn |
| 2035 | USD 399 mn |
| 2036 | USD 495 mn |
At-Home Syphilis Testing market segmentation
By test type
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Rapid antibody tests | 52.0% | 39.0% | USD 30 mn | 20.5% |
| Mail-in laboratory kits | 34.0% | 41.2% | USD 20 mn | 26.4% |
| Combined STI panels including syphilis | 14.0% | 19.8% | USD 8.1 mn | 28.4% |
By channel
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Online and direct to consumer | 54.0% | 54.5% | USD 31 mn | 24.1% |
| Pharmacy and retail | 30.0% | 32.8% | USD 17 mn | 25.1% |
| Public health programmes | 16.0% | 12.7% | USD 9.2 mn | 21.1% |
By sample type
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Blood fingerstick | 62.0% | 58.0% | USD 36 mn | 23.2% |
| Oral fluid | 18.0% | 20.0% | USD 10 mn | 25.3% |
| Urine | 8.0% | 8.0% | USD 4.6 mn | 24.0% |
| Self-collected swab | 12.0% | 14.0% | USD 6.9 mn | 25.9% |
By detection target
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Treponemal antibody | 44.0% | 40.0% | USD 25 mn | 22.8% |
| Non-treponemal antibody | 20.0% | 18.0% | USD 12 mn | 22.7% |
| Dual treponemal and non-treponemal | 36.0% | 42.0% | USD 21 mn | 25.9% |
By result delivery
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Instant read at home | 48.0% | 42.0% | USD 28 mn | 22.4% |
| Mail-in lab result | 34.0% | 36.0% | USD 20 mn | 24.7% |
| App assisted reading | 18.0% | 22.0% | USD 10 mn | 26.5% |
Top 25 countries for at-home syphilis testing by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 88.0% of 2026 revenue and the 25 countries below together hold 96.6%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 23 mn | 40.0% | USD 200 mn | 24.1% |
| 2 | United Kingdom | USD 6.9 mn | 12.0% | USD 57 mn | 23.6% |
| 3 | Canada | USD 4.0 mn | 7.0% | USD 34 mn | 23.6% |
| 4 | Germany | USD 3.5 mn | 6.0% | USD 28 mn | 23.1% |
| 5 | Brazil | USD 3.5 mn | 6.0% | USD 33 mn | 25.2% |
| 6 | Australia | USD 2.9 mn | 5.0% | USD 25 mn | 24.2% |
| 7 | France | USD 1.7 mn | 3.0% | USD 14 mn | 23.1% |
| 8 | Netherlands | USD 1.7 mn | 3.0% | USD 14 mn | 23.6% |
| 9 | Spain | USD 1.7 mn | 3.0% | USD 14 mn | 23.1% |
| 10 | South Africa | USD 1.7 mn | 3.0% | USD 16 mn | 25.2% |
| 11 | Italy | USD 0.67 mn | 1.2% | USD 5.5 mn | 23.3% |
| 12 | India | USD 0.65 mn | 1.1% | USD 5.9 mn | 24.8% |
| 13 | Mexico | USD 0.62 mn | 1.1% | USD 5.7 mn | 24.9% |
| 14 | Argentina | USD 0.54 mn | 0.9% | USD 5.0 mn | 24.9% |
| 15 | Nigeria | USD 0.40 mn | 0.7% | USD 3.7 mn | 24.9% |
| 16 | Colombia | USD 0.38 mn | 0.7% | USD 3.5 mn | 24.9% |
| 17 | Sweden | USD 0.36 mn | 0.6% | USD 2.9 mn | 23.4% |
| 18 | Ireland | USD 0.27 mn | 0.5% | USD 2.2 mn | 23.4% |
| 19 | Belgium | USD 0.21 mn | 0.4% | USD 1.7 mn | 23.3% |
| 20 | Switzerland | USD 0.18 mn | 0.3% | USD 1.5 mn | 23.6% |
| 21 | Denmark | USD 0.17 mn | 0.3% | USD 1.3 mn | 23.1% |
| 22 | New Zealand | USD 0.16 mn | 0.3% | USD 1.3 mn | 23.6% |
| 23 | Kenya | USD 0.13 mn | 0.2% | USD 1.2 mn | 25.0% |
| 24 | Chile | USD 0.13 mn | 0.2% | USD 1.1 mn | 24.6% |
| 25 | Poland | USD 98 thousand | 0.2% | USD 0.94 mn | 25.4% |
| Rest of world | USD 1.9 mn | 3.4% | USD 16 mn | 23.6% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Biosynex
- Everlywell
- LetsGetChecked
- Quest Diagnostics
- Labcorp OnDemand
Group 2: Regional and specialist players
- NOWDiagnostics
- SD Biosensor
- Abbott
- Healgen Scientific
- Wondfo
Group 3: Emerging and niche players
- myLAB Box
- Nurx
- STDcheck.com
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the at-home syphilis testing market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 24.0% is calculated from the resulting values.
The market is divided by test type, by channel, by sample type, by detection target, by result delivery. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the at-home syphilis testing market?
The global at-home syphilis testing market is estimated at USD 45 mn in 2025 and USD 58 mn in 2026.
How fast will the at-home syphilis testing market grow?
It is forecast to reach USD 495 mn by 2036, a compound annual growth rate of 24.0% from 2026, an increase of USD 437 mn.
Which country is the largest market for at-home syphilis testing?
United States is the largest market by revenue at USD 23 mn in 2026, 40.0% of the global total. The three largest countries together hold 59.0%.
Which country is growing fastest?
Among the ten largest markets, Brazil is growing fastest at 25.2% a year from 2026 to 2036.
Which at-home syphilis testing segment is largest?
In the by test type split, Rapid antibody tests is the largest segment with 52.0% of 2026 revenue.
Who are the leading at-home syphilis testing companies?
Global leaders include Biosynex, Everlywell, LetsGetChecked, Quest Diagnostics.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Colorimetric Fructosamine Assay KitUSD 57 mn · 4.8% CAGR
- Blood Bag Tube SealerUSD 58 mn · 4.5% CAGR
- Digital Colony CounterUSD 59 mn · 5.5% CAGR
- AI Aortic Surgery Planning ToolUSD 55 mn · 13.0% CAGR
- Amyotrophic Lateral Sclerosis Gene TestingUSD 62 mn · 10.5% CAGR
- Respiration Monitor BeltUSD 63 mn · 5.2% CAGR
- AI Capsule Endoscopy Reading PlatformUSD 64 mn · 17.0% CAGR
- Touch Activated Phlebotomy DevicesUSD 72 mn · 18.0% CAGR
← Assistive Robots for Disability Augmented Glenoid Systems →